BREAKING
AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 3 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 1 day ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 1 day ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 1 day ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 3 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 1 day ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 1 day ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 1 day ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago
ADVERTISEMENT
AlphaGraphs

Trxade Health (MEDS) reports 6% growth in Q1 revenue; loss widens

Pharmaceutical services company Trxade Health Inc (NASDAQ: MEDS) Monday reported a wider net loss for the first quarter of 2022 despite a 6% increase in revenues. The top-line also beat analysts’ estimates. First-quarter revenues increased 6% year-over-year to $3.2 million and came in above analysts’ estimates. The company added 339 registered members during the three-month period. […]

$MEDS May 9, 2022 1 min read
NYSE
$MEDS · Earnings

Pharmaceutical services company Trxade Health Inc (NASDAQ: MEDS) Monday reported a wider net loss for the first quarter of 2022 despite a 6% increase in revenues. The top-line also beat analysts’ estimates. First-quarter revenues increased 6% year-over-year to $3.2 million and came in above analysts’ estimates. The company added 339 registered members during the three-month period. […]

· May 9, 2022

Pharmaceutical services company Trxade Health Inc (NASDAQ: MEDS) Monday reported a wider net loss for the first quarter of 2022 despite a 6% increase in revenues. The top-line also beat analysts’ estimates.

First-quarter revenues increased 6% year-over-year to $3.2 million and came in above analysts’ estimates. The company added 339 registered members during the three-month period.

Trxade reported a net loss of $1 million or $0.12 per share for the first quarter, compared to a loss of $0.7 million or $0.08 per share in the year-ago quarter. The bottom line missed analysts’ estimates.


Check this space to read management/analysts’ comments on Trxade’s Q1 2022 results

ADVERTISEMENT

Shares of Trxade closed Monday’s trading lower. The stock has lost about 41% so far this year.

Prior Performance

  • Trxade Q4 2021 earnings infographic
  • Trxade Health Q3 2021 earnings
  • Trxade Health Q2 2021 earnings
  • Trxade Q1 2021 earnings

ADVERTISEMENT